BAIAP2L2 is a BAR/IMD domain-containing membrane adaptor protein that binds phosphoinositides and regulates membrane curvature and actin dynamics 1. Under physiological conditions, BAIAP2L2 is not essential for kidney epithelial integrity or electrolyte homeostasis 1. However, BAIAP2L2 is significantly upregulated across multiple cancer types and drives malignant progression through distinct mechanisms. In hepatocellular carcinoma, BAIAP2L2 enhances JAK1/STAT3 signaling to promote proliferation, metastasis, and PD-L1-mediated immune evasion 2, while also regulating immunity, methylation, and cuprotosis-related pathways 3. In gastric cancer, BAIAP2L2 activates AKT/mTOR and Wnt3a/β-catenin signaling pathways to increase proliferation and invasion 4, and facilitates extracellular vesicle-mediated chemoresistance transfer via m6A-dependent YTHDF1 interactions 5. In lung cancer, BAIAP2L2 supports proliferation through the Estrogen-mediated S-phase Entry pathway 6, while in prostate cancer it promotes migration and viability 7. BAIAP2L2 emerges as a pan-cancer therapeutic target with prognostic significance across multiple malignancies.